Self-injectable Therapies Tied to No Disease in 50% of Patients at 2 Years
More than half of multiple sclerosis (MS) patients treated with self-injectable therapies — namely, glatiramer acetate, marketed as Copaxone, among others, or any of a host of interferons — showed no evidence of disease activity after two years,…